ClinicalTrials.gg
CompletedNCT03413995TRIUMPHUpdated Oct 16, 2024Results posted

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

A Phase 2 interventional study of Rucaparib in Prostate Cancer Metastatic, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Completed at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing rucaparib in Prostatic Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. rucaparib · Prostatic Neoplasms.

Enrollment
7th of 10
12 · median 24
Started
2018
with 1 other
Phase 2
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 10 studies testing rucaparib in Prostatic Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 2, and was the 3rd registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 10 studies testing rucaparib in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About rucaparib

rucaparib: first FDA approval 2016 (RUBRACA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing rucaparib in Prostatic Neoplasms as a file.
02

Study summary

The aim of this research is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also referred to as metastatic hormone sensitive prostate cancer) and who have an inherited mutation in a gene involved in repairing DNA damage. The research will also examine if rucaparib is safe in individuals with metastatic prostate cancer.

Prior research studies have shown that drugs like rucaparib can be of benefit to patients with advanced metastatic prostate cancer who are resistant to androgen deprivation therapy AND who carry a mutation in a DNA repair gene. We are studying if rucaparib will be an effective treatment for these patients earlier in their treatment course (for example, prior to the start of medicines that lower testosterone level). It is unknown whether rucaparib will have the same benefit in men with metastatic prostate cancer carrying a mutation in a DNA repair gene, prior to the use of medicines that lower your testosterone level.

Read the detailed description

With respect to germline mutations, a recent study found that the incidence of inherited DNA-repair gene alterations in metastatic prostate cancer to be significantly higher (11.8%) than in both men with localized prostate cancer (4.6%) and in the general population at large (2.7%). Specifically, mutations in 7 genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51D, GEN1) were significantly enriched in patients with metastatic prostate cancer compared to the general population. These findings suggest that a subset of men are more likely to develop metastatic prostate cancer (i.e. those with germline mutations in DNA-repair genes) and may potentially benefit from PARPi therapy.

The clinical activity of PARPi in patients with DNA-repair mutations and metastatic prostate cancer has now been established. Focusing specifically on patients with a germline mutation in a pre-specified group of DNA-repair genes, we hypothesize that targeted therapy with PARPi should be sufficient to induce a clinical response irrespective of hormonal (castration-sensitive or castration-resistant) status. Our hypothesis is based largely on the data from Mateo et al showing a clinical response rate of 88% in a heavily pre-treated population of mCRPC patients with a DNA repair mutation, with the most pronounced responses being in men with germline inactivation.

For men with mHSPC, this trial would also provide an alternative to ADT. Identification of a non-hormonal based therapy is warranted as ADT is associated with a shorter time to castration resistance in men harboring a germline DNA repair mutation versus those with intact DNA repair. However, given that primary ADT (in mHSPC) is a standard first-line therapy, all patients on trial must be ineligible for or decline standard-of-care hormonal treatment. For patients with mHSPC who do not respond to PARPi, we will build safety rules into the trial design to take patients off study at first signs of progression. Primary ADT (mHSPC) would still remain a treatment option upon progression.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

Keywords

  • metastatic hormone sensitive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written and HIPAA authorization for the release of personal health information.
  • Males aged 18 years of age and above
  • Histological or cytologic proof of adenocarcinoma of the prostate
  • Germline mutation in one or more homologous recombination DNA-repair genes (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM) as documented by a clinical CLIA-grade, genetic test (including but not limited to Invitae, Color Genomics, etc)
  • All patients must be ineligible for or have declined androgen deprivation therapy (ADT)-based systemic treatment
  • Absolute PSA ≥2.0 ng/ml at screening.
  • Radiographic evidence of disease by CT scan and bone scan, performed within the prior 8 weeks.
  • Serum testosterone ≥ 100 ng/dl.
  • Participants must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • ≥ 10.0 g/dL with no blood transfusion in the past 28 days
    • (ANC) ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • Total ≤ 1.5 x institutional (ULN)
    • (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT))
  • Participants must have estimated using the Cockcroft-Gault equation of ≥51 mL/min:

    • Estimated creatinine clearance = (140-age [years]) x weight (kg) serum creatinine (mg/dL) x 72
  • Performance Status \<2
  • Participants must have a ≥ 12 months.
  • Male participants and their partners, who are sexually active and of , must agree to the use of two highly effective forms of in combination [see appendix E for acceptable methods], throughout the period of taking study treatment and for 6 months after last dose of study drug to prevent pregnancy in a partner.

Exclusion criteria

Exclusion Criteria:

  • Current active second (history of non-melanoma skin cancers and superficial bladder cancers are allowed)
  • Prior ADT in the past 6 months. Prior ADT in context of /adjuvant primary is allowed; prior ADT for biochemical recurrence is also allowed, as long as no ADT has been administered in past 6 months and testosterone has recovered (>100 ng/dl). The total duration of prior ADT should not exceed 24 months.
  • Prior oral anti-androgen (e.g. bicalutamide, nilutamide, enzalutamide, apalutamide), or androgen synthesis inhibitor (e.g. abiraterone, orteronel) in the past 6 months is not permitted. 5-alpha reductase inhibitor therapy (e.g. finasteride, dutasteride) is allowed, as long as subject has been stable on medication for past 6 months.
  • Presence of visceral (i.e. lung or liver) >3cm in long-axis dimension.
  • Pain due to bone metastases requiring narcotic analgesics.
  • Prior treatment with intravenous chemotherapy.
  • Use of any prohibited concomitant medications (Appendix B: Medications With the Potential for Drug-Drug Interactions) within the prior 2 weeks.
  • Involvement in the planning and/or conduct of the study (applies to both Clovis Oncology staff and/or staff at the study site)
  • Previous enrollment in the present study
  • Participation in another clinical study with an product during the last 1 month.
  • Any previous treatment with a PARP inhibitor, including rucaparib.
  • Resting with > 480 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
  • Persistent toxicities (>Common Terminology Criteria for Adverse Event () grade 2) caused by previous cancer therapy, excluding alopecia.
  • Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
  • Major surgery within 2 weeks of starting study treatment, and patients must have recovered from any effects of any major surgery.
  • Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 6 months) myocardial infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung disease, or any psychiatric disorder that prohibits obtaining .
  • Unable to swallow orally administered medication or gastrointestinal disorders likely to interfere with absorption of the study medication.
  • patients, e.g., patients who are known to be serologically positive for . Known active hepatitis (i.e. or C) due to risk of transmitting the infection through blood or other body fluids
  • Known to rucaparib or any of the of the product.
  • Whole blood transfusions in the last 30 days prior to entry to the study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Rucaparib 600 mg BID, continuous dosing

    Rucaparib 600mg by mouth twice daily, continuous dosing

    Drug: Rucaparib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Prostate Specific Antigen (PSA) >=50 Response

    Response Rate(PSA) Prostate Specific Antigen to rucaparib for patients with metastatic hormone sensitive prostate cancer harboring germline mutation in homologous recombination DNA (Deoxyribonucleic acid) repair gene. Measured by decline in PSA to 50% of baseline, confirmed with second measurement at least 4 weeks apart.

    Time frame: 4 weeks

Secondary outcomes

  1. Number of Participants With Treatment-related Adverse Events

    As assessed by CTCAE v4.0

    Time frame: 4 years 8 months

  2. PSA Progression-free Survival

    Defined as a time (months) from initiation of rucaparib therapy until PSA increase of 25 %, confirmed with another measurement at least 3 weeks later

    Time frame: 2 years

  3. Progression-free Survival

    Defined as time (months) from initiation of rucaparib therapy to radiographic or clinical progression or death, whichever comes first.

    Time frame: 2 years

  4. Objective Response

    Defined as patients achieving a complete or partial response in target lesions found on radiographic scans among patients who have measurable disease at baseline.

    Time frame: 2 years

07

Results

Posted Oct 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneRucaparib 600 mg BID
Started12
Completed12
Not completed0

Outcome measures

PrimaryNumber of Participants With Prostate Specific Antigen (PSA) >=50 Response

Response Rate(PSA) Prostate Specific Antigen to rucaparib for patients with metastatic hormone sensitive prostate cancer harboring germline mutation in homologous recombination DNA (Deoxyribonucleic acid) repair gene. Measured by decline in PSA to 50% of baseline, confirmed with second measurement at least 4 weeks apart.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Prostate Specific Antigen (PSA) >=50 Response
ParticipantsRucaparib 600 mg BID
Number of Participants With Prostate Specific Antigen (PSA) >=50 Response5
SecondaryNumber of Participants With Treatment-related Adverse Events

As assessed by CTCAE v4.0

Time frame:
4 years 8 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events
ParticipantsRucaparib 600 mg BID
Number of Participants With Treatment-related Adverse Events12
SecondaryPSA Progression-free Survival

Defined as a time (months) from initiation of rucaparib therapy until PSA increase of 25 %, confirmed with another measurement at least 3 weeks later

Time frame:
2 years
Reported as:
Median · months
PSA Progression-free Survival
monthsRucaparib 600 mg BID
PSA Progression-free Survival11.2 (3.7 to NA)
SecondaryProgression-free Survival

Defined as time (months) from initiation of rucaparib therapy to radiographic or clinical progression or death, whichever comes first.

Time frame:
2 years
Reported as:
Median · months
Progression-free Survival
monthsRucaparib 600 mg BID
Progression-free Survival12 (8.0 to NA)
SecondaryObjective Response

Defined as patients achieving a complete or partial response in target lesions found on radiographic scans among patients who have measurable disease at baseline.

Time frame:
2 years
Reported as:
Count of participants · Participants
Objective Response
ParticipantsRucaparib 600 mg BID
Objective Response3

Adverse events

Collected over Baseline to End of Treatment approximately 4 years 8 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rucaparib 600 mg BID0/12 (0%)3/12 (25%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventRucaparib 600 mg BID
Small Bowel ObstructionGastrointestinal disorders1/12
Atrial FibrillationCardiac disorders1/12
PneumoniaRespiratory, thoracic and mediastinal disorders1/12
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRucaparib 600 mg BID
FatigueGeneral disorders8/12
Aspartate Aminotransferase-increasedBlood and lymphatic system disorders7/12
Alanine Aminotransferase-IncreasedBlood and lymphatic system disorders7/12
Creatinine-IncreasedBlood and lymphatic system disorders6/12
NauseaGastrointestinal disorders6/12
DysguesiaNervous system disorders5/12
DiarrheaGastrointestinal disorders4/12
AnemiaBlood and lymphatic system disorders4/12
Palmar-Plantar Erythrodyesia SyndromeSkin and subcutaneous tissue disorders2/12
Skin RashSkin and subcutaneous tissue disorders2/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rucaparib 600 mg BID, Continuous Dosing
<=18 years0
Between 18 and 65 years4
>=65 years8
Age, Continuous
Age, Continuous(years)Rucaparib 600 mg BID, Continuous Dosing
Median68 (49 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Rucaparib 600 mg BID, Continuous Dosing
Female0
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rucaparib 600 mg BID, Continuous Dosing
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Rucaparib 600 mg BID, Continuous Dosing
United States12
08

Study locations

2 sites
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
09

References and documents

Publications

  • Nientiedt C, Duensing A, Zschabitz S, Jager D, Hohenfellner M, Stenzinger A, Duensing S. PARP inhibition in prostate cancer. Genes Chromosomes Cancer. 2021 May;60(5):344-351. doi: 10.1002/gcc.22903. Epub 2020 Oct 28. PubMed 33084183 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Nov 2023, 61 months.

Results were first posted in Oct 2024, 11 months after primary completion.

Of 612 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 61 months is close to that.

Counting every sponsor, half of 726 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2018
First posted
Jan 29, 2018
StartActual
Sep 10, 2018
Primary completionActual
Nov 8, 2023
CompletionActual
Sep 12, 2024
Results first posted
Oct 16, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03413995
Collaborators
Clovis Oncology, Inc.
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Sep 10, 2018
Primary completion
Nov 8, 2023
Completion
Sep 12, 2024
Results posted
Oct 16, 2024
Last update
Oct 16, 2024

Study contacts

Mark Markowski, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rucaparib

Start the discussion